Search results
13 mar 2023 · Cold urticaria is a chronic condition causing episodic symptoms of cold-induced wheals or angioedema in response to direct or indirect exposure to cold temperatures. Whereas symptoms of cold urticaria are typically benign and self-limiting, severe systemic anaphylactic reactions are possible.
MANAGEMENT OF COLD URTICARIA SYNDROMES. The decision to treat cold urticaria syndromes depends primarily on the underlying etiology, severity of response to cold stimulus, and how greatly it affects quality of life, including the frequency of anticipated cold exposure.
Our systematic review included 16 studies, 9 of which met the eligibility criteria for the meta-analysis. We analyzed the effects of treatments on critical temperature thresholds (CTTs) and critical stimulation time thresholds (CSTTs), as well as on rates of complete response and adverse events.
Guidelines for cold urticaria management established by the Centre of Evidence of Dermatology and the Urticaria Group of the French Society of Dermatology, British Journal of Dermatology , Volume 190, Issue 3, March 2024, Pages 445–447,
27 wrz 2021 · This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria. Abbreviations. AAS. Angioedema activity score. ACARE. Angioedema Center of Reference and Excellence. ACE.
11 lip 2021 · In cold urticaria, skin exposure to cold is the relevant trigger. Patients with cold urticaria show itchy wheal and flare type skin reactions or angioedema at exposed skin sites, typically within minutes after cold contact (cold air, cold liquids or objects).
18 paź 2021 · patients. The pooled prevalence of anaphylaxis among patients with cold urticaria was 21.49% (95% CI, 15.79% to 28.54%; I2 69%). CONCLUSIONS: [ Cold urticaria constitutes an appreciable proportion of CIndU and CU cases and is predominantly managed with H1-antihistamines; few patients receive omalizu-mab.
